Skip to main content
OpenTrials

Clinical trial condition

Pathologic Stage III Esophageal Adenocarcinoma AJCC v8

Explore clinical trials studying Pathologic Stage III Esophageal Adenocarcinoma AJCC v8. Study availability and eligibility vary by location and protocol.

10 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Pathologic Stage III Esophageal Adenocarcinoma AJCC v8 trial results

Completed

Use of Trifluridine/Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma

NCT04097028

Conditions
Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, +13 more
Locations
  • Roswell Park Cancer Institute Buffalo, New York, United States
  • Stephenson Oklahoma Cancer Center at the University of Oklahoma Health Science Center Oklahoma City, Oklahoma, United States
View Trial Details
Active, Not Recruiting

Testing the Addition of the Anti-cancer Viral Therapy Telomelysin™ to Chemoradiation for Patients With Advanced Esophageal Cancer and Are Not Candidates for Surgery

NCT04391049

Conditions
Advanced Esophageal Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Carcinoma, +36 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • City of Hope South Pasadena South Pasadena, California, United States
  • City of Hope Upland Upland, California, United States
  • Moffitt Cancer Center Tampa, Florida, United States
View all 17 locations
View Trial Details
Active, Not Recruiting

Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers

NCT04460937

Conditions
Adenocarcinoma Of Esophagus, Brain Diseases, Brain Neoplasms, +80 more
Locations
  • City of Hope Comprehensive Cancer Center Duarte, California, United States
  • Northwestern University Chicago, Illinois, United States
  • University of Kentucky/Markey Cancer Center Lexington, Kentucky, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
View Trial Details

Related conditions